RGLS vs. RIGL, ALIM, EBS, MACK, VSTM, BOLT, VNDA, XOMA, LXRX, and CRVO
Should you be buying Regulus Therapeutics stock or one of its competitors? The main competitors of Regulus Therapeutics include Rigel Pharmaceuticals (RIGL), Alimera Sciences (ALIM), Emergent BioSolutions (EBS), Merrimack Pharmaceuticals (MACK), Verastem (VSTM), Bolt Biotherapeutics (BOLT), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Lexicon Pharmaceuticals (LXRX), and CervoMed (CRVO). These companies are all part of the "pharmaceutical preparations" industry.
Rigel Pharmaceuticals (NASDAQ:RIGL) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.
Regulus Therapeutics received 30 more outperform votes than Rigel Pharmaceuticals when rated by MarketBeat users. However, 68.81% of users gave Rigel Pharmaceuticals an outperform vote while only 63.49% of users gave Regulus Therapeutics an outperform vote.
66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are owned by institutional investors. 9.0% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 4.4% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Regulus Therapeutics had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 3 mentions for Regulus Therapeutics and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.75 beat Regulus Therapeutics' score of -0.33 indicating that Regulus Therapeutics is being referred to more favorably in the news media.
Rigel Pharmaceuticals currently has a consensus price target of $5.81, indicating a potential upside of 416.67%. Regulus Therapeutics has a consensus price target of $7.25, indicating a potential upside of 170.52%. Given Regulus Therapeutics' higher possible upside, equities research analysts plainly believe Rigel Pharmaceuticals is more favorable than Regulus Therapeutics.
Rigel Pharmaceuticals has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.
Rigel Pharmaceuticals has higher revenue and earnings than Regulus Therapeutics. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Regulus Therapeutics has a net margin of 0.00% compared to Regulus Therapeutics' net margin of -21.47%. Regulus Therapeutics' return on equity of 0.00% beat Rigel Pharmaceuticals' return on equity.
Summary
Regulus Therapeutics beats Rigel Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Regulus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RGLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regulus Therapeutics Competitors List
Related Companies and Tools
